Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
BRKR 
Bruker Corporation (BRKR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/31/2025: BRKR (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
14 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $46.45
1 Year Target Price $46.45
| 5 | Strong Buy |
| 2 | Buy |
| 7 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 15.11% | Avg. Invested days 31 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 10/31/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 5.91B USD | Price to earnings Ratio 74.88 | 1Y Target Price 46.45 |
Price to earnings Ratio 74.88 | 1Y Target Price 46.45 | ||
Volume (30-day avg) 14 | Beta 1.2 | 52 Weeks Range 28.49 - 64.39 | Updated Date 11/2/2025 |
52 Weeks Range 28.49 - 64.39 | Updated Date 11/2/2025 | ||
Dividends yield (FY) 0.55% | Basic EPS (TTM) 0.52 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-11-04 | When Before Market | Estimate 0.32 | Actual - |
Profitability
Profit Margin 2.31% | Operating Margin (TTM) 3.61% |
Management Effectiveness
Return on Assets (TTM) 3.55% | Return on Equity (TTM) 4.07% |
Valuation
Trailing PE 74.88 | Forward PE 13.83 | Enterprise Value 7627685482 | Price to Sales(TTM) 1.72 |
Enterprise Value 7627685482 | Price to Sales(TTM) 1.72 | ||
Enterprise Value to Revenue 2.22 | Enterprise Value to EBITDA 18.91 | Shares Outstanding 151719365 | Shares Floating 103140342 |
Shares Outstanding 151719365 | Shares Floating 103140342 | ||
Percent Insiders 31.98 | Percent Institutions 84.05 |
Upturn AI SWOT
Bruker Corporation
Company Overview
History and Background
Bruker Corporation was founded in 1960 by Gu00fcnther Laukien. It initially focused on nuclear magnetic resonance (NMR) technology. Over the decades, it expanded into various analytical and diagnostic technologies through organic growth and acquisitions.
Core Business Areas
- Bruker BioSpin Group: Develops, manufactures, and distributes high-performance scientific instruments for NMR, electron paramagnetic resonance (EPR), and preclinical magnetic resonance imaging (MRI).
- Bruker CALID Group: Offers mass spectrometry, gas chromatography, ion mobility spectrometry, and related software and consumables for chemical analysis, life science research, and applied markets.
- Bruker Scientific Instruments (BSI) NANO Group: Provides atomic force microscopy (AFM), stylus and optical metrology, X-ray diffraction (XRD) and X-ray fluorescence (XRF) instruments for materials research and industrial quality control.
- Bruker Scientific Instruments (BSI) BEST Group: Offerings include infrared and Raman molecular spectroscopy instruments, as well as fluorescence microscopy and advanced X-ray microscopy technologies for life science and materials science applications.
Leadership and Structure
Bruker is led by its CEO, Frank Laukien. The company operates with a decentralized organizational structure, with several operating groups focusing on specific product lines and markets. It has a board of directors overseeing the company's overall strategy and performance.
Top Products and Market Share
Key Offerings
- NMR Spectrometers: Bruker is a leading provider of NMR spectrometers used in pharmaceutical research, materials science, and other applications. They hold a significant market share (estimated around 40%). Competitors include Thermo Fisher Scientific and JEOL.
- Mass Spectrometers: Bruker's mass spectrometers are used for proteomics, metabolomics, and other analytical applications. Market share is estimated around 15%-20%. Competitors include Thermo Fisher Scientific, Agilent, and Waters Corporation.
- Atomic Force Microscopes (AFM): Bruker's AFMs are used for nanoscale imaging and characterization in materials science, biology, and other fields. Bruker is a market leader for AFM, with an estimated market share of 30-35%. Competitors include Oxford Instruments Asylum Research and Keysight Technologies.
Market Dynamics
Industry Overview
The analytical and diagnostic instrument industry is driven by innovation in life sciences, materials science, and industrial applications. Growth is fueled by increasing R&D spending, stricter regulatory requirements, and demand for advanced analytical capabilities.
Positioning
Bruker is a leading provider of high-end analytical instrumentation. The company differentiates itself through its technological leadership, comprehensive product portfolio, and strong customer support. It has a strong position in key markets such as NMR, mass spectrometry, and AFM.
Total Addressable Market (TAM)
The total addressable market for analytical instrumentation is estimated at over $70 billion USD. Bruker Corporation is positioned to capture a significant portion of this market, focusing on high-value segments with strong growth potential.
Upturn SWOT Analysis
Strengths
- Technological leadership in key product areas
- Strong brand reputation
- Diversified product portfolio
- Global sales and service network
- High customer retention rates
Weaknesses
- High R&D expenses
- Exposure to economic cycles
- Competition from larger players in some segments
- Integration challenges with acquired companies
Opportunities
- Growing demand for analytical instrumentation in emerging markets
- Increasing adoption of advanced technologies in life sciences and materials science
- Potential for further acquisitions and partnerships
- Expanding into new applications and markets
Threats
- Intense competition
- Technological obsolescence
- Economic downturns
- Regulatory changes
- Supply chain disruptions
Competitors and Market Share
Key Competitors
- Thermo Fisher Scientific (TMO)
- Agilent Technologies (A)
- Waters Corporation (WAT)
Competitive Landscape
Bruker competes with larger and smaller companies in various segments. It differentiates itself through its technological expertise and focus on high-end applications. Bruker's acquisitions have strengthened its competitive position.
Major Acquisitions
ProSpectus
- Year: 2022
- Acquisition Price (USD millions): 30
- Strategic Rationale: Enhanced Bruker's MALDI Biotyper capabilities by incorporating rapid microbial identification via Raman spectroscopy.
InVivo
- Year: 2021
- Acquisition Price (USD millions): 34
- Strategic Rationale: Addition of Optical Microscopy capabilities to the life science research portfolio.
Growth Trajectory and Initiatives
Historical Growth: Bruker has achieved consistent revenue and earnings growth over the past decade, driven by both organic growth and acquisitions.
Future Projections: Analysts expect Bruker to continue growing revenue at a mid-single-digit rate over the next several years, driven by demand for its analytical instruments in life sciences, materials science, and industrial applications.
Recent Initiatives: Recent strategic initiatives include expanding into new markets, investing in R&D to develop new products and technologies, and acquiring complementary businesses.
Summary
Bruker Corporation is a strong player in the analytical instrumentation market, with technological strengths and a diversified portfolio. It benefits from growing demand in life sciences and materials science. However, it faces competition and needs to manage R&D expenses and integration risks carefully. The company is well positioned to capture future growth opportunities. Bruker needs to watch out for technology obsoletion and economic downturns.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Bruker Corporation Annual Reports
- SEC Filings
- Analyst Reports
- Industry Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data are estimates and may vary depending on the source. Financial data is based on publicly available information and may be subject to change. Actual results may differ materially from projections.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Bruker Corporation
Exchange NASDAQ | Headquaters Billerica, MA, United States | ||
IPO Launch date 2000-08-04 | Chairman, CEO & President Dr. Frank H. Laukien Ph.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 11396 | Website https://www.bruker.com |
Full time employees 11396 | Website https://www.bruker.com | ||
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. It offers magnetic resonance spectroscop, preclinical imaging, biopharma and applied, services and lifecycle support, integrated data solution, and automation; life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper platform for bacterial and fungal identification and establish, DNA test strips, and; genotype and fluorotype molecular diagnostics kits; and research, analytical, and process analysis instruments and solutions. It provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. The company was founded in 1960 and is headquartered in Billerica, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.